BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34426664)

  • 1. Estimating the population health impact of a multi-cancer early detection genomic blood test to complement existing screening in the US and UK.
    Hackshaw A; Cohen SS; Reichert H; Kansal AR; Chung KC; Ofman JJ
    Br J Cancer; 2021 Nov; 125(10):1432-1442. PubMed ID: 34426664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Potential Value-Based Price of a Multi-Cancer Early Detection Genomic Blood Test to Complement Current Single Cancer Screening in the USA.
    Tafazzoli A; Ramsey SD; Shaul A; Chavan A; Ye W; Kansal AR; Ofman J; Fendrick AM
    Pharmacoeconomics; 2022 Nov; 40(11):1107-1117. PubMed ID: 36038710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient Preferences for Multi-Cancer Early Detection (MCED) Screening Tests.
    Gelhorn H; Ross MM; Kansal AR; Fung ET; Seiden MV; Krucien N; Chung KC
    Patient; 2023 Jan; 16(1):43-56. PubMed ID: 35844011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Exploratory Analysis of the Cost-Effectiveness of a Multi-cancer Early Detection Blood Test Compared with Standard of Care Screening in Ontario, Canada.
    Lewis D; Wong WWL; Lipscomb J; Horton S
    Pharmacoeconomics; 2024 Apr; 42(4):393-407. PubMed ID: 38150120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attitudes to multi-cancer early detection (MCED) blood tests for population-based screening: A qualitative study in Great Britain.
    Schmeising-Barnes N; Waller J; Marlow LAV
    Soc Sci Med; 2024 Apr; 347():116762. PubMed ID: 38520825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA.
    Chen X; Dong Z; Hubbell E; Kurtzman KN; Oxnard GR; Venn O; Melton C; Clarke CA; Shaknovich R; Ma T; Meixiong G; Seiden MV; Klein EA; Fung ET; Liu MC
    Clin Cancer Res; 2021 Aug; 27(15):4221-4229. PubMed ID: 34088722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set.
    Klein EA; Richards D; Cohn A; Tummala M; Lapham R; Cosgrove D; Chung G; Clement J; Gao J; Hunkapiller N; Jamshidi A; Kurtzman KN; Seiden MV; Swanton C; Liu MC
    Ann Oncol; 2021 Sep; 32(9):1167-1177. PubMed ID: 34176681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-cancer early detection test in symptomatic patients referred for cancer investigation in England and Wales (SYMPLIFY): a large-scale, observational cohort study.
    Nicholson BD; Oke J; Virdee PS; Harris DA; O'Doherty C; Park JE; Hamady Z; Sehgal V; Millar A; Medley L; Tonner S; Vargova M; Engonidou L; Riahi K; Luan Y; Hiom S; Kumar H; Nandani H; Kurtzman KN; Yu LM; Freestone C; Pearson S; Hobbs FR; Perera R; Middleton MR
    Lancet Oncol; 2023 Jul; 24(7):733-743. PubMed ID: 37352875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-cancer early detection blood test using machine learning detects early-stage cancers lacking USPSTF-recommended screening.
    Vittone J; Gill D; Goldsmith A; Klein EA; Karlitz JJ
    NPJ Precis Oncol; 2024 Apr; 8(1):91. PubMed ID: 38632333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New genomic technologies for multi-cancer early detection: Rethinking the scope of cancer screening.
    Hackshaw A; Clarke CA; Hartman AR
    Cancer Cell; 2022 Feb; 40(2):109-113. PubMed ID: 35120599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical and economic benefits associated with novel multi-cancer early detection tests: conference highlights from the 2022 ISPOR Annual Meeting.
    Nabavizadeh N
    Am J Manag Care; 2022 Aug; 28(7 Suppl):S123-S132. PubMed ID: 36067342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Projecting the impact of multi-cancer early detection on late-stage incidence using multi-state disease modeling.
    Lange JM; Gogebakan KC; Gulati R; Etzioni R
    Cancer Epidemiol Biomarkers Prev; 2024 Mar; ():. PubMed ID: 38506751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of screening participation on modelled mortality benefits of a multi-cancer early detection test by socioeconomic group in England.
    Smittenaar R; Quaife SL; von Wagner C; Higgins T; Hubbell E; Lee L
    J Epidemiol Community Health; 2024 May; 78(6):345-353. PubMed ID: 38429085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study.
    Schrag D; Beer TM; McDonnell CH; Nadauld L; Dilaveri CA; Reid R; Marinac CR; Chung KC; Lopatin M; Fung ET; Klein EA
    Lancet; 2023 Oct; 402(10409):1251-1260. PubMed ID: 37805216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating cell-free DNA-based multi-cancer early detection.
    Zhang K; Fu R; Liu R; Su Z
    Trends Cancer; 2024 Feb; 10(2):161-174. PubMed ID: 37709615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Addressing positive multi-cancer early detection tests in head and neck Surgery: Experience with head and neck work up for high-risk referrals.
    Fearington FW; Zhao CY; Romero-Brufau S; Moore EJ; Price DL; Tasche KK; Yin LX; Kunkel ET; Kisiel JB; Giridhar KV; Routman DM; Van Abel KM
    Oral Oncol; 2024 May; 152():106809. PubMed ID: 38621326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-Cancer Early Detection: The New Frontier in Cancer Early Detection.
    Guerra CE; Sharma PV; Castillo BS
    Annu Rev Med; 2024 Jan; 75():67-81. PubMed ID: 37729031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes following a false positive multi-cancer early detection (MCED) test: Results from DETECT-A, the first large, prospective, interventional MCED study.
    Lennon AM; Buchanan AH; Rego SP; Choudhry OA; Elias PZ; Sadler JR; Roberta J; Zhang Y; Flake DD; Honushefsky A; Salvati ZM; Sheridan K; Wagner ES; Fishman EK; Papadopoulos N; Beer TM
    Cancer Prev Res (Phila); 2024 May; ():. PubMed ID: 38705577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage Shift as an Endpoint in Cancer Screening Trials: Implications for Evaluating Multicancer Early Detection Tests.
    Owens L; Gulati R; Etzioni R
    Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1298-1304. PubMed ID: 35477176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.